Total Payments
$177,763
2024 Payments
$88.94
Companies
11
Transactions
51
Payment Breakdown by Category
Research$162,981 (91.7%)
Consulting$7,000 (3.9%)
Other$4,399 (2.5%)
Travel$1,747 (1.0%)
Food & Beverage$1,637 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $162,981 | 20 | 91.7% |
| Consulting Fee | $7,000 | 3 | 3.9% |
| Long term medical supply or device loan | $2,399 | 1 | 1.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,000 | 1 | 1.1% |
| Travel and Lodging | $1,747 | 7 | 1.0% |
| Food and Beverage | $1,637 | 19 | 0.9% |
Payments by Type
Research
$162,981
20 transactions
General
$14,782
31 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boston Scientific Corporation | $153,582 | 17 | $0 (2023) |
| PFIZER INC. | $9,486 | 6 | $0 (2023) |
| Sorin Group USA Inc. | $5,000 | 1 | $0 (2017) |
| Lantheus Medical Imaging, Inc. | $4,355 | 13 | $0 (2018) |
| Butterfly Network, Inc. | $2,399 | 1 | $0 (2021) |
| EISAI INC. | $2,000 | 1 | $0 (2018) |
| Siemens Medical Solutions USA, Inc. | $412.18 | 5 | $0 (2024) |
| Edwards Lifesciences Corporation | $290.42 | 3 | $0 (2019) |
| Medtronic, Inc. | $102.31 | 1 | $0 (2023) |
| Abbott Laboratories | $97.78 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $88.94 | 1 | Siemens Medical Solutions USA, Inc. ($88.94) |
| 2023 | $3,612 | 8 | PFIZER INC. ($3,216) |
| 2021 | $3,669 | 3 | Butterfly Network, Inc. ($2,399) |
| 2020 | $106,240 | 11 | BOSTON SCIENTIFIC CORPORATION ($103,740) |
| 2019 | $52,443 | 10 | Boston Scientific Corporation ($49,771) |
| 2018 | $2,424 | 5 | EISAI INC. ($2,000) |
| 2017 | $9,285 | 13 | Sorin Group USA Inc. ($5,000) |
All Payment Transactions
51 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/22/2024 | Siemens Medical Solutions USA, Inc. | — | Food and Beverage | In-kind items and services | $88.94 | General |
| 12/11/2023 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $16.41 | General |
| 10/12/2023 | Siemens Medical Solutions USA, Inc. | — | Food and Beverage | In-kind items and services | $86.26 | General |
| 08/21/2023 | Abbott Laboratories | AVEIR (Device) | Food and Beverage | In-kind items and services | $51.18 | General |
| Category: Cardiac Rhythm Management | ||||||
| 08/20/2023 | Abbott Laboratories | ENSITE (Device) | Food and Beverage | In-kind items and services | $46.60 | General |
| Category: Electrophysiology | ||||||
| 06/19/2023 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $71.92 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 06/17/2023 | Impulse Dynamics (USA) Inc. | OPTIMIZER (Device), OPTIMIZER | Food and Beverage | Cash or cash equivalent | $37.59 | General |
| Category: Cardiovascular Device | ||||||
| 06/08/2023 | Medtronic, Inc. | MICRA (Device) | Food and Beverage | In-kind items and services | $102.31 | General |
| Category: Pacemakers | ||||||
| 01/23/2023 | PFIZER INC. | VYNDAMAX (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: VYNDAMAX CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
| 08/30/2021 | PFIZER INC. | VYNDAQEL (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TAFAMIDIS CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
| 04/14/2021 | Butterfly Network, Inc. | Butterfly IQ (Device) | Long term medical supply or device loan | Cash or cash equivalent | $2,399.00 | General |
| Category: Ultrasound Imaging | ||||||
| 03/30/2021 | PFIZER INC. | VYNDAQEL (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TAFAMIDIS CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
| 12/21/2020 | PFIZER INC. | VYNDAQEL (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/01/2020 | BOSTON SCIENTIFIC CORPORATION | CLINICAL TRIAL PRODUCT (Device) | — | Cash or cash equivalent | $4,634.50 | Research |
| Study: REPRISE IV • Category: CLINICAL TRIAL PRODUCT | ||||||
| 07/29/2020 | BOSTON SCIENTIFIC CORPORATION | CLINICAL TRIAL PRODUCT (Device) | — | Cash or cash equivalent | $19,142.50 | Research |
| Study: REPRISE IV • Category: CLINICAL TRIAL PRODUCT | ||||||
| 07/29/2020 | BOSTON SCIENTIFIC CORPORATION | CLINICAL TRIAL PRODUCT (Device) | — | Cash or cash equivalent | $5,440.50 | Research |
| Study: REPRISE IV • Category: CLINICAL TRIAL PRODUCT | ||||||
| 07/14/2020 | BOSTON SCIENTIFIC CORPORATION | CLINICAL TRIAL PRODUCT (Device) | — | Cash or cash equivalent | $10,244.00 | Research |
| Study: REPRISE IV • Category: CLINICAL TRIAL PRODUCT | ||||||
| 06/10/2020 | BOSTON SCIENTIFIC CORPORATION | CLINICAL TRIAL PRODUCT (Device) | — | Cash or cash equivalent | $20,351.50 | Research |
| Study: REPRISE IV • Category: CLINICAL TRIAL PRODUCT | ||||||
| 06/10/2020 | BOSTON SCIENTIFIC CORPORATION | CLINICAL TRIAL PRODUCT (Device) | — | Cash or cash equivalent | $9,672.00 | Research |
| Study: REPRISE IV • Category: CLINICAL TRIAL PRODUCT | ||||||
| 04/07/2020 | BOSTON SCIENTIFIC CORPORATION | LOTUS EDGE (Device) | — | Cash or cash equivalent | $5,843.50 | Research |
| Study: REPRISE IV • Category: CATHETERS | ||||||
| 03/04/2020 | BOSTON SCIENTIFIC CORPORATION | CLINICAL TRIAL PRODUCT (Device) | — | Cash or cash equivalent | $10,881.00 | Research |
| Study: REPRISE IV • Category: CLINICAL TRIAL PRODUCT | ||||||
| 02/05/2020 | BOSTON SCIENTIFIC CORPORATION | CLINICAL TRIAL PRODUCT (Device) | — | Cash or cash equivalent | $10,881.00 | Research |
| Study: REPRISE IV • Category: CLINICAL TRIAL PRODUCT | ||||||
| 02/05/2020 | BOSTON SCIENTIFIC CORPORATION | CLINICAL TRIAL PRODUCT (Device) | — | Cash or cash equivalent | $6,649.50 | Research |
| Study: REPRISE IV • Category: CLINICAL TRIAL PRODUCT | ||||||
| 12/04/2019 | Boston Scientific Corporation | GENERAL STRUCTURAL HEART (Device) | — | Cash or cash equivalent | $13,500.50 | Research |
| Study: REPRISE IV • Category: STRUCTURAL HEART | ||||||
| 10/30/2019 | Boston Scientific Corporation | CLINICAL TRIAL PRODUCT (Device) | — | Cash or cash equivalent | $10,881.00 | Research |
| Study: REPRISE IV • Category: CLINICAL TRIAL PRODUCT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| REPRISE IV | BOSTON SCIENTIFIC CORPORATION | $103,740 | 10 |
| REPRISE IV | Boston Scientific Corporation | $49,771 | 6 |
| Perceval S Sutureless Heart Valve Study TPS002 | Sorin Group USA Inc. | $5,000 | 1 |
| VYNDAMAX CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| TAFAMIDIS CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
About Dr. Neil Weissman, MD
Dr. Neil Weissman, MD is a Cardiovascular Disease healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1851332175.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Neil Weissman, MD has received a total of $177,763 in payments from pharmaceutical and medical device companies, with $88.94 received in 2024. These payments were reported across 51 transactions from 11 companies. The most common payment nature is "" ($162,981).
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Washington, DC
- Active Since 06/09/2006
- Last Updated 04/20/2011
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1851332175
Products in Payments
- CLINICAL TRIAL PRODUCT (Device) $134,167
- GENERAL STRUCTURAL HEART (Device) $13,501
- VYNDAQEL (Drug) $6,270
- LOTUS EDGE (Device) $5,844
- Aortic Tissue Valve - Perceval (Device) $5,000
- Definity (Drug) $4,355
- VYNDAMAX (Drug) $3,200
- Butterfly IQ (Device) $2,399
- Belviq (Drug) $2,000
- Edwards SAPIEN 3 Transcatheter Heart Valve (Device) $254.61
- SC2000 (Device) $136.73
- MICRA (Device) $102.31
- WATCHMAN FLX (Device) $71.92
- AVEIR (Device) $51.18
- ENSITE (Device) $46.60
- OPTIMIZER (Device) $37.59
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Washington
Dr. Toby Rogers
Cardiovascular Disease — Payments: $812,095
Cardiovascular Disease $812,095
Hayder Hashim, M.d, M.D
Cardiovascular Disease — Payments: $573,299
Cardiovascular Disease $573,299
Dr. Joshua Yamamoto, M.d, M.D
Cardiovascular Disease — Payments: $423,212
Cardiovascular Disease $423,212
Zayd Eldadah, Md, Phd, MD, PHD
Cardiovascular Disease — Payments: $379,254
Cardiovascular Disease $379,254
Mardi Gomberg-Maitland, Md, MD
Cardiovascular Disease — Payments: $305,036
Cardiovascular Disease $305,036
Jonathan Reiner, M.d, M.D
Cardiovascular Disease — Payments: $220,893
Cardiovascular Disease $220,893